DC
Decheng Capital Portfolio holdings
AUM
$396M
This Quarter Return
-9.88%
1 Year Return
-5.21%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$466M
AUM Growth
+$466M
(+10%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
22.52%
Top 10 Holdings %
Top 10 Hldgs %
83.67%
Holding
30
New
4
Increased
10
Reduced
5
Closed
2
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$54M |
| 2 |
CG Oncology
CGON
|
$25.6M |
| 3 |
Revolution Medicines
RVMD
|
$9.8M |
| 4 |
Lyell Immunopharma
LYEL
|
$7.62M |
| 5 |
Aclaris Therapeutics
ACRS
|
$5.62M |
Top Sells
| 1 |
Phathom Pharmaceuticals
PHAT
|
$4.51M |
| 2 |
GeneDx Holdings
WGS
|
$4.4M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
$2.33M |
| 4 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$1.88M |
| 5 |
Arcus Biosciences
RCUS
|
$908K |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$2.04B
| $183M | 39.2% | 6,371,669 +892,859 | +16% | +$25.6M |
|
2
Nuvation Bio
NUVB
$1.02B
| $69M | 14.81% | 25,954,439 | – | – |
|
|
UPB
3
Upstream Bio, Inc. Common Stock
UPB
$923M
| $54M | 11.58% | +3,285,293 | New | +$54M |
|
4
NewAmsterdam Pharma
NAMS
$2.71B
| $19.8M | 4.24% | 770,000 +180,000 | +31% | +$4.63M |
|
5
Illumina
ILMN
$15.8B
| $12.7M | 2.72% | 94,767 | – | – |
|
|
6
Arcus Biosciences
RCUS
$1.13B
| $12M | 2.58% | 808,789 -61,001 | -7% | -$908K |
|
7
Krystal Biotech
KRYS
$4.27B
| $12M | 2.58% | 76,772 +5,000 | +7% | +$783K |
|
|
8
Revolution Medicines
RVMD
$7.1B
| $9.89M | 2.12% | 226,000 +224,000 | +11,200% | +$9.8M |
|
9
MoonLake Immunotherapeutics
MLTX
$3.54B
| $9.29M | 1.99% | 171,600 +5,000 | +3% | +$271K |
|
10
Crinetics Pharmaceuticals
CRNX
$2.92B
| $8.59M | 1.84% | 167,958 +10,000 | +6% | +$511K |
|
11
BeyondSpring
BYSI
$69.4M
| $7.96M | 1.71% | 4,882,651 -75,492 | -2% | -$123K |
|
12
Merus
MRUS
$4.98B
| $7.95M | 1.71% | 189,098 | – | – |
|
|
13
Lyell Immunopharma
LYEL
$213M
| $7.62M | 1.63% | +11,909,341 | New | +$7.62M |
|
|
14
Zentalis Pharmaceuticals
ZNTL
$122M
| $7.08M | 1.52% | 2,338,095 -770,000 | -25% | -$2.33M |
|
15
Arcellx
ACLX
$3.85B
| $6.47M | 1.39% | 84,377 +63,200 | +298% | +$4.85M |
|
|
16
Phathom Pharmaceuticals
PHAT
$864M
| $5.64M | 1.21% | 694,254 -555,746 | -44% | -$4.51M |
|
|
17
Aclaris Therapeutics
ACRS
$209M
| $5.62M | 1.21% | +2,266,667 | New | +$5.62M |
|
18
Legend Biotech
LEGN
$6.41B
| $5M | 1.07% | 153,558 +45,000 | +41% | +$1.46M |
|
19
Cytokinetics
CYTK
$4.23B
| $4.7M | 1.01% | 100,000 +5,957 | +6% | +$280K |
|
20
BioNTech
BNTX
$24B
| $4.56M | 0.98% | +40,000 | New | +$4.56M |
|
21
Aura Biosciences
AURA
$389M
| $4.24M | 0.91% | 515,555 | – | – |
|
22
Equillium
EQ
$62.2M
| $3.33M | 0.71% | 4,447,308 | – | – |
|
23
4D Molecular Therapeutics
FDMT
$288M
| $2.23M | 0.48% | 400,000 +2,165 | +0.5% | +$12.1K |
|
24
Vera Therapeutics
VERA
$1.38B
| $2.1M | 0.45% | 49,767 -20,000 | -29% | -$846K |
|
25
AtriCure
ATRC
$1.84B
| $819K | 0.18% | 26,797 | – | – |
|